STUDY SEARCH RESULTS

1 study found for your search request:  V503-069

Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vacci...
Condition: Papillomavirus Infections
Minimum Age: 9 years, Maximum Age: 26 years
Gender: All
Study ID: NCT04708041
Status: Active, not recruiting




Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  U.S. Corporate Site